Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
about
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactionsAnalysis of Genetic Variation in CYP450 Genes for Clinical ImplementationA model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysisEfficacy of S-1 in colorectal cancer.Advancing the medical management of epilepsy: disease modification and pharmacogenetics.CYP2D6 polymorphisms in patients with porphyriasGenetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).Drug bioactivation, covalent binding to target proteins and toxicity relevance.Characterization of ADME gene variation in 21 populations by exome sequencing.Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.Cytochrome p450 assays.Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients.Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.CYP-nsSNP: a specialized database focused on effect of non-synonymous SNPs on function of CYPs.Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.Cyp4a14 overexpression induced by hyperoxia in female CBA mice as a possible contributor of increased resistance to oxidative stress.Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals.
P2860
Q24643366-EAA0EE08-096B-4561-9F0D-AA8BB227C3D1Q28468449-59D9910F-1949-4EF4-9C34-B38743A6217DQ33324419-14891A8E-C675-4EFC-9B19-9DAD84FB821FQ33385984-440BD883-49B6-4110-B230-52028697DCC5Q33424985-3C66BD9C-356E-4B3C-ACEB-A65DAE93B61BQ33433129-8CBA1BC7-D06E-4017-9AD8-ABFFEF9F519BQ34429445-8D724BB8-0EA6-43E6-8273-F26915EC7232Q34579490-3642C476-879B-4244-9213-634032A90354Q35586929-431BF864-3925-4E72-BE7E-9AFAEB64A8FAQ35753607-ADC07F05-69D3-45F6-A304-354975677E4CQ35754239-C074FEEF-C668-4F9C-A156-915500F0024BQ36061821-BFB2D6A2-86A1-442C-BD7A-78BD0BF5F871Q37619264-3DF446B0-E6C6-4BC6-A93F-D51A904551ABQ37625226-44111DEF-0E46-4683-AA9A-C1445B6FB9C9Q37631831-FC44C2B5-5E07-4CCD-8933-7FA192461B77Q37889959-1BC603E2-2931-46B4-A933-229B32DE6F33Q38133562-E348F406-C811-404D-9C4A-DF523D4DCB5BQ39065445-01BB9601-A6FC-4A40-B1F7-CD96AF42F84FQ42047832-BC27804D-A423-4A09-BD34-71E4C468E976Q42726484-57B22F4F-47D7-4C6E-B7D5-F0EAD1E25BE9Q43650364-62E3ECB2-416B-40D7-A5C1-46A1BC87324DQ44161614-EEFFA958-A341-4D87-AF73-C99FA821D357Q45729383-BD7D98F0-F013-4AC9-8A64-BEF1EB91E576Q46765977-05B070B1-C91E-4ED2-A536-8C8E0C37F68DQ46828988-FA488CA5-CD79-4CD5-B337-3E9EADBD3754Q47328233-54E2ABD9-3BCA-4122-B695-AAD5841A1E92Q47872739-4B102AE3-15D4-4774-8036-188C8CB30DB5Q48610657-807CFA44-DD5E-48F2-A18A-BC89D67F52E3Q51604173-A21C0FD9-3E50-4D36-BB94-CE0A8BEBEEEDQ51620668-844F023C-6BCF-45A2-8550-A170B3F68815
P2860
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@ast
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@en
type
label
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@ast
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@en
prefLabel
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@ast
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@en
P1476
Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
@en
P2093
J van der Weide
L S Steijns
P304
P356
10.1177/000456329903600604
P478
36 ( Pt 6)
P577
1999-11-01T00:00:00Z